Arecor Therapeutics PLC (AREC) - Net Assets
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has net assets worth GBX6.45 Million GBX (≈ $785.27 USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX8.10 Million ≈ $985.66 USD) and total liabilities (GBX1.65 Million ≈ $200.39 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Arecor Therapeutics PLC's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX6.45 Million |
| % of Total Assets | 79.67% |
| Annual Growth Rate | 20.18% |
| 5-Year Change | -65.21% |
| 10-Year Change | N/A |
| Growth Volatility | 731.64 |
Arecor Therapeutics PLC - Net Assets Trend (2017–2025)
This chart illustrates how Arecor Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Arecor Therapeutics PLC stock valuation.
Annual Net Assets for Arecor Therapeutics PLC (2017–2025)
The table below shows the annual net assets of Arecor Therapeutics PLC from 2017 to 2025. Also explore AREC net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX6.45 Million ≈ $785.27 |
+20.66% |
| 2024-12-31 | GBX5.35 Million ≈ $650.82 |
-43.85% |
| 2023-12-31 | GBX9.53 Million ≈ $1.16K |
-45.42% |
| 2022-12-31 | GBX17.45 Million ≈ $2.12K |
-5.90% |
| 2021-12-31 | GBX18.55 Million ≈ $2.26K |
+2297.17% |
| 2020-12-31 | GBX773.79K ≈ $94.15 |
-75.88% |
| 2019-12-31 | GBX3.21 Million ≈ $390.31 |
-23.91% |
| 2019-05-31 | GBX4.22 Million ≈ $512.95 |
+528.92% |
| 2018-05-31 | GBX670.33K ≈ $81.56 |
-49.66% |
| 2017-05-31 | GBX1.33 Million ≈ $162.01 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Arecor Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3797226000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX378.00K | 5.86% |
| Other Comprehensive Income | GBX2.22 Million | 34.35% |
| Other Components | GBX46.14 Million | 714.89% |
| Total Equity | GBX6.45 Million | 100.00% |
Arecor Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Arecor Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AFFINOR GROWERS INC.
F:1AF0
|
$402.14K |
|
Dewata Freight International Tbk PT
JK:DEAL
|
$402.97K |
|
Sleep Number Corp
NASDAQ:SNBR
|
$403.36K |
|
Hill Street Beverage Company Inc
V:HILL
|
$403.71K |
|
Kendrick Resources PLC
LSE:KEN
|
$397.75K |
|
CABASSE S.A. EO -50
F:LB0
|
$397.26K |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
$396.07K |
|
Anexo Group Plc
LSE:ANX
|
$393.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arecor Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,349,000 to 6,454,000, a change of 1,105,000 (20.7%).
- Net income of 664,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 13,028,001.
- Other factors increased equity by 13,469,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX664.00K | +10.29% |
| Other Comprehensive Income | GBX-13.03 Million | -201.86% |
| Other Changes | GBX13.47 Million | +208.69% |
| Total Change | GBX- | 20.66% |
Book Value vs Market Value Analysis
This analysis compares Arecor Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 534.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3613.59x to 534.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-05-31 | GBX0.02 | GBX87.50 | x |
| 2019-05-31 | GBX0.15 | GBX87.50 | x |
| 2019-12-31 | GBX0.12 | GBX87.50 | x |
| 2020-12-31 | GBX0.03 | GBX87.50 | x |
| 2021-12-31 | GBX0.81 | GBX87.50 | x |
| 2022-12-31 | GBX0.60 | GBX87.50 | x |
| 2023-12-31 | GBX0.31 | GBX87.50 | x |
| 2024-12-31 | GBX0.16 | GBX87.50 | x |
| 2025-12-31 | GBX0.16 | GBX87.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arecor Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.29%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 38.74%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.26x
- Recent ROE (10.29%) is above the historical average (-111.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -166.97% | -82.90% | 0.65x | 3.08x | GBX-1.19 Million |
| 2019 | -57.77% | -325.72% | 0.14x | 1.29x | GBX-2.86 Million |
| 2019 | -68.25% | -115.79% | 0.44x | 1.34x | GBX-2.51 Million |
| 2020 | -355.70% | -162.13% | 0.40x | 5.54x | GBX-2.83 Million |
| 2021 | -33.26% | -532.73% | 0.06x | 1.13x | GBX-8.02 Million |
| 2022 | -53.05% | -385.35% | 0.11x | 1.25x | GBX-11.01 Million |
| 2023 | -89.79% | -187.05% | 0.30x | 1.61x | GBX-9.51 Million |
| 2024 | -191.36% | -202.57% | 0.58x | 1.63x | GBX-10.77 Million |
| 2025 | 10.29% | 38.74% | 0.21x | 1.26x | GBX18.60K |
Industry Comparison
This section compares Arecor Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $500,672
- Average return on equity (ROE) among peers: -385.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arecor Therapeutics PLC (AREC) | GBX6.45 Million | -166.97% | 0.26x | $401.97K |
| 4BASEBIO UK SOCIETAS (4BB) | $-492.00K | 0.00% | 0.00x | $1.06 Million |
| Aptamer Group PLC (APTA) | $304.00K | -2577.63% | 8.06x | $106.65K |
| Avacta Group PLC (AVCT) | $14.00K | -764.29% | 1.36x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $2.72 Million | -40.97% | 0.11x | $14.84K |
| Bioventix (BVXP) | $-71.00K | 0.00% | 0.00x | $985.36K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $1.67 Million | -80.55% | 0.34x | $77.17K |
| CRISM Therapeutics Corporation (CRTX) | $15.21 Million | -4.50% | 0.05x | $93.94K |
| Fusion Antibodies PLC (FAB) | $323.00K | 0.00% | 1.18x | $154.88K |
| Faron Pharmaceuticals Oy (FARN) | $-15.16 Million | 0.00% | 0.00x | $485.05K |
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a no… Read more